结构治疗公司的股价在减肥药在试验中平均减肥15.3%后达到52周的高点. Structure Therapeutics shares hit a 52-week high after its weight loss drug showed 15.3% average weight loss in trials.

Structure Therapeutics Inc.股价在公布其实验性减重药物阿仑列磷酸临床试验的积极成果后，跃升至52周高点94.90美元。 Structure Therapeutics Inc. shares jumped to a 52-week high of $94.90 after the company reported positive top-line results from a clinical trial of its experimental weight loss drug, aleniglipron. GLP-1受体激动剂原为一次日间口服药物,导致接受高剂量治疗的病人平均体重下降15.3磅,约35.5磅,大大超过安慰剂,具有有利的安全性。 The once-daily oral medication, a GLP-1 receptor agonist, led to an average weight loss of 15.3%—about 35.5 pounds—in patients receiving a high dose, significantly more than placebo, with a favorable safety profile. 公司计划将aleniglipron推进到第三阶段试验,预计将于2026年中期开始,此前投资者对新型肥胖治疗的强烈响应和日益增长的兴趣引起了关注. The company plans to advance aleniglipron into Phase 3 trials, expected to start in mid-2026, following strong investor response and growing interest in novel obesity treatments.